
Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal
Revolution Medicines has signed a massive $2 billion deal with Royalty Pharma to support the biotech’s portfolio of RAS(ON) inhibitors and extend its cash runway for the foreseeable future. The deal will provide Revolution with the $2 billion in committed …